Vandetanib

ALTERNATE NAME: N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; ZD6474, Zactima

CATALOG #: 1751-25, 100

AMOUNT: 25 mg, 100 mg

STRUCTURE:



MOLECULAR FORMULA: $C_{22}H_{24}BrFN_4O_2$

MOLECULAR WEIGHT: 475.35

CAS NUMBER: 443913-73-3

APPEARANCE: White solid

SOLUBILITY: DMSO (30 mg/ml) or EtOH (10 mg/ml)

PURITY: ≥98% by HPLC

STORAGE: Store at -20 ℃

DESCRIPTION: A potent inhibitor of kinase insert domain-containing receptor [KDR/vascular endothelial growth factor receptor (VEGFR) 2] tyrosine kinase activity (IC_{50} = 40 nM). This compound also inhibits fms-like tyrosine kinase 4 (VEGFR3, IC_{50} = 110 nM) and epidermal growth factor receptor (EGFR/HER1, IC_{50} = 500 nM) but shows selectivity relating to a range of other tyrosine and serine-threonine kinases.

REFERENCE: Wedge, S.R., *et al.* (2002). *Cancer Res.* 62, 4645-4655.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

FOR RESEARCH USE ONLY! Not to be used on humans.

RELATED PRODUCTS:

- Bosutinib **(Cat. No. 1584-5, 25)**
- Dasatinib **(Cat. No. 1586-25, 100)**
- Erlotinib, Hydrochloride **(Cat. No. 1588-100, 1000)**
- Gefitinib **(Cat. No. 1589-5, 25)**
- Imatinib Mesylate **(Cat. No. 1625-100, 1000)**
- Lapatinib Ditosylate **(Cat. No. 1624-25, 100)**
- Nilotinib **(Cat. No. 1750-25, 100)**
- Sorafenib **(Cat. No. 1594-25, 100)**
- Sunitinib Malate **(Cat. No. 1611-100, 1000)**

BioVision Incorporated
155 S. Milpitas Boulevard, Milpitas, CA 95035 USA

Tel: 408-493-1800 | Fax: 408-493-1801
www.biovision.com | tech@biovision.com